Healthcare stocks have moved higher as investors have favored defensive businesses and reassessed the sector’s valuation. Energy led the market.
Eli Lilly, Merck and AbbVie were among the pharmaceutical contributors, while hospital operators HCA Healthcare and Universal Health Services also rose. Elevance Health, formerly known as Anthem, gained 15% over the period, and Universal Health Services advanced 21%.
Some of the move has been linked to expectations about the Nov. 3 midterm elections. Analysts have said Democratic gains in Congress could delay or soften Medicaid reimbursement reductions enacted under last year’s spending law, while a Democratic sweep could also increase healthcare subsidies. A House-only change is viewed as less likely to produce major healthcare legislation, and a stronger progressive presence could make bipartisan agreement harder.
The sector’s appeal also reflects its breadth. Healthcare includes drugmakers, biotechnology companies, hospitals, insurers, medical-device manufacturers and healthcare-technology businesses. Screening criteria used in a current sector review favored companies with projected long-term earnings growth of at least 8%, forward price-to-earnings ratios no higher than 19, at least seven analysts covering them and consensus Buy ratings. The examples meeting those criteria included AbbVie and Cigna among dividend payers, alongside Organon, Teleflex, DaVita, Centene and Humana.
The rally is not explained by elections alone. Investors have also shifted toward other defensive groups as enthusiasm for the earlier artificial-intelligence trade has cooled. Healthcare therefore combines a policy-sensitive rally with the sector’s established attraction as a source of recurring demand, but its companies remain exposed to reimbursement decisions, drug-pricing policy and the differing economics of pharmaceuticals, hospitals and insurers.